When nanoparticle-based mRNA COVID-19 vaccines were made available in December 2020 and the media began to report the incidence of rare but troubling anaphylaxis, nanomedicine experts including Frederick National Laboratory’s Marina Dobrovolskaia recognized those hypersensitivity reactions.
“Everything they reported symptomatically sounded so…
A nanoparticle-based flu vaccine discovered and developed by the Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), was manufactured by Frederick National Laboratory (FNL) for a Vaccine Research Center Phase 1 clinical trial. The vaccine was found to be safe, well-tolerated, and immunogenic against multiple flu…
The Chemical Biology Consortium (CBC) within the National Cancer Institute Experimental Therapeutics (NExT) Program is a government, academic, and industry partnership to help translate promising discoveries into anticancer therapeutics.
Managed by the Frederick National Laboratory, NExT CBC provides the expertise to advance…
Seven Columbia University graduate students recently completed drug discovery projects at the Frederick National Laboratory for Cancer Research (FNL) as part of their fall 2021 semester. Since 2020, 40 Columbia University students have completed projects with the FNL for their master’s degree coursework.
The projects represent a partnership…
The Nanotechnology Characterization Laboratory is working with industry partners to bolster the use of nanotechnology in drug development and delivery as the interest in the promising technology expands.
“Pharma has initially been hesitant to get into nano because it’s too much risk versus reward,” said Jeffrey D. Clogston, Ph.D., the…
A grim statistic is driving Steven Rosenberg’s mission to find new cancer treatments—and his partnership with Frederick National Laboratory (FNL) to do so.
“Every year in the United States, about 600,000 people die of cancer, 90% of whom die of the solid epithelial cancers,” said Rosenberg, the M.D., Ph.D., chief of the National Cancer…
The Frederick National Laboratory for Cancer Research and biotech company Progenra, Inc., recently signed a contractor Cooperative Research and Development Agreement (cCRADA) to develop a novel therapy that could be capable of degrading KRAS.
The human KRAS gene is one of the most elusive and potentially promising cancer therapy targets.…
Since its inception, the Biopharmaceutical Development Program has manufactured more than 250 lots of 100 different biopharmaceuticals to support human clinical studies, including:
Proteins and peptides
Monoclonal antibodies (murine/humanized/chimeric)
The Biopharmaceutical Development Program offers resources for and expertise in the development of investigational biological products that move promising treatments for cancer, rare diseases, AIDS, and infectious diseases into clinical trials.
The program provides leading-edge development and analytical…
The use of nanotechnology has become common in the pharmaceutical industry due to the benefits that nanoparticles offer to drug delivery, vaccines, immunotherapies, and medical devices. The Nanotechnology Characterization Laboratory has characterized over 400 nanotechnology-based concepts, 17 of which advanced to clinical trials.…